Novartis (NVS.US) has again received clinical approval for a new triple-antibody drug in China, targeting systemic lupus erythematosus.

The latest announcement on the official website of the Center for Drug Evaluation (CDE) of the National Pharmaceutical Administration of China states that Novartis (NVS.US) has obtained a new implied permission for a clinical trial of the class 1 new drug PIT565.

Zhitong FinanceFeb 8 20:19

Express News | Bio-Thera Solutions: The application for marketing authorization of Sicu-kiu-mab injection has been accepted.

BreakingsFeb 7 16:50

Novartis Rises 5% Since Q4 Earnings: How Should You Play the Stock?

Zacks Feb 6 22:05

AlphaValue/Baader Europe: Novartis Shares 'Hold More Value' After Strong FY24

MT NewswiresFeb 6 17:53

Goldman Sachs Sticks to Their Hold Rating for Novartis AG (NOVN)

TipRanksFeb 6 15:35 · Ratings

Novartis AG (NVS): Among the Best Foreign Dividend Stocks to Invest In Now

Yahoo FinanceFeb 5 23:13